Though less well known than Ebola virus, Marburg virus is a filovirus in the same disease family that causes hemorrhagic fever and has a fatality rate of up to 88%. There are currently no approved vaccines or therapeutics to treat individuals infected with the virus.
In 2019 EIDB conducted a Phase 1 trial to evaluate a Marburg vaccine product developed by the Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH).
The trial, which was conducted at WRAIR’s Clinical Trial Center with 40 healthy adult volunteers, evaluated the safety tolerability and immunogenicity of an investigational recombinant chimpanzee adenovirus Type 3-vectored Marburg virus vaccine.